TriMark Publications, LLC’s Report “Molecular Diagnostics in Cancer Testing” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/25/2011 -- Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays.

These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide.

Buy Now: http://www.reportsnreports.com/reports/75216-molecular-diagnostics-in-cancer-testing.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

TriMark Publications, LLC’s Report “Companion Diagnostics in Personalized Medicine and Cancer Therapy” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/19/2011 -- A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs. Adoption of biomarker development in clinical research provides great opportunities to identify patient subpopulations with differential drug responses and to uncover the underlying mechanisms.

These data could help to explain if clinical trials of new drugs are adequate, and offer the possibility of creating a clear prescription path based on predictive biomarkers. The purpose of this TriMark Publications report is to describe the specific segment of the diagnostics market that develops new technology platforms for evaluating the metabolism of therapeutic agents, or for evaluating which therapeutic regimes are most effective for a particular type of disease. The term companion diagnostic means that the particular diagnostic test under evaluation is specifically linked to a known therapeutic drug. This linkage could be important in the therapeutic application and clinical outcome of a drug (personalized medicine), or an important component of the drug development process. This report focuses on the former linkage, i.e., the use of companion diagnostic tests in personalized medicine.

Buy Now: http://www.reportsnreports.com/reports/75195-companion-diagnostics-in-personalized-medicine-and-cancer-therapy.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

TriMark Publications, LLC’s Report “Drugs of Abuse Testing Markets” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/15/2011 -- This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) market known as drugs of abuse testing. In the current medical diagnostics market, drugs of abuse testing offers promise for significant growth and innovation. Examined in this study are assays for alcohol, cannabinoids, cocaine, amphetamines, opiates and phencyclidine, as well as assays for addictive prescription drugs such as OxyContin.

Moreover, special attention is paid to Substance Abuse and Mental Health Service Administration (SAMHSA) requirements, which aims to prevent substance abuse in the U.S. and so requires that certain corporations comply with anti-drug policies and testing. This review covers the leading market players, the competitive landscape, and the promising pipeline products in the drugs of abuse testing markets. Specifically, areas examined in this study include: available and developing technologies in the field, the U.S. and global market size for drugs of abuse tests, and the profiles of companies that are focusing on the drugs of abuse testing market. Detailed charts with sales forecasts and market share data for the U.S. and global drugs of abuse testing markets are included.

Buy Now: http://www.reportsnreports.com/reports/94529-drugs-of-abuse-testing-markets.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

iData Research’s Report “International Hyaluronic Acid Viscosupplementation Physician Survey 2011” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/15/2011 -- Over 100 orthopedic specialists were surveyed regarding their perceptions and usage of hyaluronic acid viscosupplementation during the 2011 American Academy of Orthopaedic Surgeons (AAOS) conference. This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid viscosupplement product, including single injection, 3-injection and 5-injection therapy regimes. Satisfaction with current offerings is examined in detail, along with the market penetration of single injection products.

The data presented describes practice experience, practice volume and the attitudes of the respondents to the product, as well as how these factors interact. In addition to physician brand preference, this survey report describes the proportion of doctors who would be willing to switch to a single injection product like Genzyme's Synvisc-One®. The results of the survey indicated a high degree of familiarity with the product within the physician community. There is a general divide in the U.S. medical community between HA brands that are used for a majority of procedures within a practice. The respondents were asked to rate their satisfaction with the various injection products. This in term was compared to the probability of switching brands, and the possible motivating reasons for doing so.

The executive summary of this report is also available for purchase.
TABLE OF CONTENTS
TABLE OF CONTENTS .I
LIST OF FIGURES.IV
LIST OF CHARTS VII
EXECUTIVE SUMMARY . 1
1.1 OVERVIEW 1
1.2 RESPONDENT PRACTICE LOCATION
1.3 COMPETING BRANDS
1.4 PURCHASING CHANNELS
1.5 IMPORTANCE OF PRICING .
1.6 SATISFACTION WITH SINGLE INJECTION.
1.7 PURCHASING DECISIONS.
1.8 TIME TO PAIN RELIEF AFTER HA TREATMENT
SURVEY HIGHLIGHTS
2.1 RESPONDENT CHARACTERISTICS .
2.1.1 Doctor Profile .
2.1.2 Purchasing Channel .
2.2 RESPONSE SUMMARY .
2.2.1 Attitudes Towards Products
2.2.2 Product Incentives
2.2.3 Patient Profile.
2.2.4 Brand Preferences
RESEARCH METHODOLOGY.
3.1 RESEARCH OVERVIEW
3.2 RESEARCH SERVICES
3.3 SURVEY METHODOLOGY
Step 1: Project Initiation & Team Selection .
Step 2: Sample Population Preparation .
Table of Contents
Step 3: Preparation, Questionnaire Design & Administration.
Step 4: Reporting and Analysis.
Step 5: Customer Feedback
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS

Buy Now: http://www.reportsnreports.com/reports/90353-international-hyaluronic-acid-viscosupplementation-physician-surv.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

GBI Research’s Report “Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/11/2011 -- GBI Research, leading business intelligence provider, has released its latest research report, 'Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure', which provides insights into major drug failures during 2005-2010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 1996-2009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development.

GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost of development for new therapeutic agents. The main cause of drug failure in Phase III, when the efficacy of the drug is already evaluated, is either its safety measures or its ability to demonstrate any additional benefits in a larger population over a longer time period. Pharmaceutical companies have recently invested substantial amounts of money in R&D processes; in order to combat the threat of patent expires of blockbuster drugs, and to increase the chances of discovering a drug which could generate considerable revenue for the company. If a drug receives approval and is patented, companies' returns are significantly higher than the amount invested in R&D.

The attrition of molecules occurs at various stages of the trial during drug development process. The majority of molecules fail at the initial stages of development, such as pre-clinical studies and Phase I and II. Pharmaceutical companies face huge losses when drugs fail in the late stage of trials, such as Phase III and the post-marketing stage.

According to analysis conducted during 2005-2010, it was found that the number of drugs dropped from the pipeline increased from 2003 to 2007 and furthermore decreased from 2007 to 2010. Many drugs have been discontinued during the course of clinical trials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis. If the drug is not able to demonstrate any additional benefits over existing therapies, or it has issues related to patient safety, the drug fails to receive approval from health authorities.

Scope
•Identification of top 20 R&D drug failures
•Unmet need in efficacy and safety for all failed drugs
•Phase II results and the reasons for conducting Phase III
•The reasons for failure and lack of available options for a particular therapeutic area
•Conclusion regarding late-stage drug failures based on the analysis of the top 20 drug failures

Reasons to buy
•Build an understanding of recent top R&D late stage drug failures
•Analyze the effect of safety and efficacy parameters on major drug failures
•Identify the unmet needs for a particular indication with the highest drug failures
•Understand the most common reasons for drug failure in late stage of development
•Identify the cost involved in R&D by analyzing the expenditure done by top pharmaceutical companies

Buy Now: http://www.reportsnreports.com/reports/93024-top-rd-drug-failures-toxicity-and-serious-adverse-events-in-la.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

GBI Research’s Report “Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market “is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/06/2011 -- GBI Research, the leading business intelligence provider, has released its latest report, "Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market" which provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Brazil. The report provides a comprehensive insight of the reasons for outsourcing clinical trials to Brazil and the key services provided by the Clinical Research Organizations (CROs) of Brazil. The report provides a detailed analysis of the Brazilian market in terms of its size, and major service offerings of the CROs in Brazil. The report also discusses the factors that are driving the clinical trial market in Brazil. The report delves into the key documents required by the investigator and the sponsor before, during and after the conduct of clinical trials. The report also provides key alliances between the CROs of other countries and the local CROs of Brazil. Furthermore, the report looks into the major challenges that can restrict the growth of the clinical trials market in Brazil.

Scope
The report analyses the clinical trial market in Brazil, along with the major forces driving the current market and the potential challenges that could restrain the growth. The scope of the report includes -
- The need for outsourcing clinical trials to Brazil.
- Trends in clinical trial registration in Brazil and a comparative analysis of clinical trial registration in Brazil, Russia, India and China (BRIC) and six major Latin American countries.
- Analysis of the key drivers that are fueling the growth of the clinical trial market in Brazil.
- Analysis of the key infrastructural facilities, clinical research professionals and principal investigators in Brazil.
- Analysis of key government regulations in Brazil affecting the clinical trial market.
- Study of 13 major CROs operating in Brazil with SWOT analysis of large multinational CROs.

Reasons to buy

The report will enhance your decision making capability in a rapid and time-sensitive manner. It will allow you to -
- Compare the key capabilities of major clinical trial service providers with your requirements and optimize your R&D costs.
- Develop market entry and market expansion strategies by identifying the key drivers and challenges in the Brazilian clinical trials market.
- Develop effective strategies to maximize the advantages in Brazil through understanding of the regulatory environment.
- Understand the regulatory structure in Brazil and key documents required to register clinical trials in Brazil.

Buy Now:http://www.reportsnreports.com/reports/90363-emerging-market-for-clinical-trials-in-brazil-improved-guidelin.html

Browse All:http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm